Chest
CommentaryBronchial Thermoplasty: Reappraising the Evidence (or Lack Thereof)
Section snippets
A Brief Overview of Airway Smooth Muscles and Thermoplasty
Thermoplasty involves applying radiofrequency energy to selectively ablate airway smooth muscle (ASM) in visible proximal airways (typically up to the subsegmental level). Early animal studies documented selective loss of ASM without significant fibrosis, epithelial injury, or structuring.3 The distal airways (< 2-3 mm in diameter) account for about 10% of the total airway resistance in a normal person. However, in asthma, there exists a continuum of inflammation all the way from the proximal
AIR-2 Trial Design
The AIR-2 trial was a high-quality multicenter (multinational) double-blind sham-controlled study that randomized patients with severe asthma on a 2:1 basis to bronchial thermoplasty vs sham thermoplasty. A total of 288 patients were analyzed, of which 190 subjects underwent bronchial thermoplasty and 98 subjects underwent sham thermoplasty (2:1 randomization). It is important to note that the sham procedure was elaborate and mimicked the actual thermoplasty procedure in every way except for
AIR-2 Trial Results: Primary and Secondary End Points
The primary end point of the AIR-2 trial was the change in the Asthma Quality of Life Questionnaire (AQLQ) from baseline to 12 months. The AQLQ has 32 items in four domains: activities (12 items), asthma symptoms (11 items), emotional function (five items), and environmental exposure (four items). The minimal clinically important difference for the AQLQ is determined to be 0.5 (range, 0.42-0.58), with higher scores (a greater positive change) indicating improved asthma-related quality of life
AIR-2 Trial Results: Unplanned Analysis of Health-care Use
The AIR-2 trial also reported on some other end points that had not been prospectively included in their planned analysis. These included unscheduled physician office visits, ED visits, and hospitalizations (Table 1). A quick look at Table 1 would make one realize that these three outcomes are interlinked. For example, a patient who was hospitalized was also likely to have visited the ED and also to be simultaneously classified as having had a severe asthma episode. This is a very important
Clinical vs Statistical Significance
How are we to interpret the AIR-2 results? As noted above, if one were to use routine frequentist statistical methods (eg, a t test), the AQLQ difference of 0.19 between the two groups would not reach statistical significance (P = .2).15 In fact, even in the AIR-2 trial, this primary end point did not reach statistical significance. The AIR-2 trial used Bayesian statistics to analyze the primary and secondary end points. The concept of posterior probability of success (PPS) was used their
Editorial Controversy
The original AIR-2 trial had an accompanying editorial that did point out flaws in the trial design (lack of run-in period) and results (statistical but lack of clinical significance regarding the AQLQ difference between groups).13 Very surprisingly, exactly 1 year after the original editorial, the same authors wrote an unsolicited letter to the editor sharply criticizing the AIR-2 trial design and reporting methodology.15 They rightfully pointed out that the outcomes based on which the FDA
Problems With the AIR-2 Postapproval Follow-up Studies
A number of post-approval safety and efficacy studies have been published, and we now have 5-year postthermoplasty safety and efficacy data.17, 18 The biggest criticism regarding these studies is the absence of any information regarding outcomes in the sham group. One must again recall the large improvement in AQLQ of 1.16 in the sham group. This beneficial effect was likely a result of the more diligent and protocol-driven asthma care they received as part of the AIR-2 trial. These benefits
Critical Importance of Having a Sham-Controlled Arm in Asthma Trials
Asthma is a poorly defined entity with vast intersubject variability in disease perception, disease severity, and quality of life. The power of the placebo has been long recognized (and skillfully exploited) in medicine.20 Several sham-controlled trials of arthroscopy, vertebroplasty, and so forth have all upended decades of conventional wisdom regarding the usefulness of those procedures.21, 22 The placebo effect is particularly well recognized in asthma, and this aspect was elegantly
FDA Device Approval Process
Bronchial thermoplasty was approved by the FDA in 2010 based on a single pivotal trial. This process is based on the 1997 FDA modernization act (aka FDAMA), which allowed for “one or more clinical investigations” to be the new standard for device approval, replacing the previous standard, which required that clinical investigations be required prior to a new device approval. This innocuous-sounding change in the approval process allowed for medical device approval based on just one positive
Conclusions
Current marketing of thermoplasty highlights its use for patients with severe asthma, which is interpreted by most clinicians as meaning oral corticosteroid dependence, frequent exacerbations, or a significantly reduced FEV1 with a poor QOL. These types of patients were specifically excluded from the AIR-2 trial. We all care for patients with severe asthma for whom existing treatment options appear ineffective. We owe it to these patients to accept only the highest standards for efficacy,
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
References (25)
- et al.
Inflammation of small airways in asthma
J Allergy Clin Immunol
(1997) - et al.
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
J Allergy Clin Immunol
(2001) - et al.
Determining a minimal important change in a disease-specific Quality of Life Questionnaire
J Clin Epidemiol
(1994) - et al.
Counterpoint: efficacy of bronchial thermoplasty for patients with severe asthma. Is there sufficient evidence? Not yet
Chest
(2011) - et al.
Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma
Ann Allergy Asthma Immunol
(2011) FDA approves new device for adults with severe and persistent asthma. US Food and Drug Administration website
- et al.
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial
Am J Respir Crit Care Med
(2010) - et al.
Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs
J Appl Physiol (1985)
(2004) The role of small airway inflammation in asthma
Allergy Asthma Proc
(2002)Part III: Location of asthma inflammation and the distal airways: clinical implications
Curr Med Res Opin
(2007)
The role of small airway disease in asthma
Curr Opin Pulm Med
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J
Cited by (35)
Phenotype- and patient-specific modelling in asthma: Bronchial thermoplasty and uncertainty quantification
2020, Journal of Theoretical BiologyAdvances in Bronchial Thermoplasty
2016, ChestBronchial thermoplasty: A review of the evidence
2016, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :No intubations or pneumothoraces were reported.5,25 Another consideration in the 5-year follow-up study for the AIR-2 trial is that the information regarding outcomes in the sham group was not reported, which produces difficulty in interpreting the actual benefits of thermoplasty.27 One factor that makes the evaluation of the efficacy of BT in treating patients with asthma difficult is the lack of consistency throughout most of the clinical trials.
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes
2015, Journal of Allergy and Clinical ImmunologyGuidelines for severe uncontrolled asthma
2015, Archivos de BronconeumologiaCitation Excerpt :A recent study, with a 5-year follow-up, showed a sustained improvement in disease control (reduction in number of severe exacerbations and visits to the emergency room) and confirmed the safety of the procedure51 (evidence B-R2). It is currently recommended only in experienced units and in the research setting1,52 (evidence D-R2)53 (evidence B-R2). Although no controlled trials have been performed in severe asthma, theophylline as a single agent has relatively weak anti-inflammatory activity, but at low doses it can markedly enhance the action of corticosteroids on the expression of inflammatory genes54 (evidence D-R2).
Response
2015, ChestCitation Excerpt :This is not true. Given the importance of the subject matter, we made sure that the manuscript underwent careful and close scrutiny before publication.1 Our reasons for going ahead with publishing the Commentary are well reflected by the response of Drs Iyer and Lim.3
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.